Progeria triple-therapy findings ‘disappointing’

Pravastatin and zoledronic acid provide no additional clinically relevant benefit to lonafarnib monotherapy for patients with Hutchinson-Gilford progeria syndrome, study findings indicate.
Source: MedWire News - Category: Consumer Health News Tags: Cardiology Source Type: news